-
House subcommittee members questioned why Emergent BioSoultions awarded bonuses to executives despite quality problems than hindered production of Johnson & Johnson's COVID-19 vaccine.
-
Thursday's tally was India's highest since the pandemic began – more than double the previous 2020 peak.
-
Government health officials are recommending a "pause" in vaccinations with the Johnson & Johnson COVID-19 vaccine. We're answering your questions as we learn more.
-
The German chancellor announces an intensified coronavirus lockdown going into Easter, warning that new mutations raise the specter of a potentially deadly "third wave" of COVID-19.
-
"Its benefits continue to be far greater than its risks," said Dr. Sabine Straus of the agency's risk committee. It found no increase in the overall risk of blood clots with the vaccine.
-
Emergent BioSolutions is under contract with Operation Warp Speed to make COVID-19 vaccines, but the terms could allow employees and their families to get vaccinated ahead of schedule.
-
It takes time after vaccination for immunity to the virus to build up, and no vaccine is 100% effective. Plus, scientists don't yet know if the vaccine stops viral spread. Here's what's known so far.
-
Almost 150,000 people in India have died from complications of COVID-19, behind only the U.S. and Brazil. India plans to begin inoculating its population of 1.4 billion this month.
-
The state-owned Sinopharm says its vaccine has a 79% efficacy rate — surpassing the widely accepted standard of 50% efficacy.
-
Dr. Peter Hotez is part of a team working to develop a low-cost COVID vaccine that could be distributed globally. "Vaccines are coming," he says. "We have to get everybody through to the other side."